Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Protein Page:
BIRC2 (human)
rdtyret
p Phosphorylation
ac Acetylation
me Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
ub Ubiquitylation
sm Sumoylation
ne Neddylation
gl O-GlcNAc
ga O-GalNAc
pa Palmitoylation
ad Adenylation
sn S-Nitrosylation
ca Caspase cleavage
sc Succinylation

Overview
BIRC2 Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin- protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin- protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, TRAF2, DIABLO/SMAC, MAP3K14/NIK, MAP3K5/ASK1, IKBKG/NEMO and MXD1/MAD1. Can also function as an E3 ubiquitin- protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Can stimulate the transcriptional activity of E2F1. Plays a role in the modulation of the cell cycle. Interacts with DIABLO/SMAC and with PRSS25; these interactions inhibit apoptotic suppressor activity. Interacts with CASP9. Interacts (via BIR domains) with TRAF2. Interacts with E2F1, RIPK1, RIPK2, RIPK3, RIPK4, BIRC5/survivin and USP19. Present in many fetal and adult tissues. Mainly expressed in adult skeletal muscle, thymus, testis, ovary, and pancreas, low or absent in brain and peripheral blood leukocytes. The CARD domain inhibits the activation of E3 ubiquitin ligase activity by preventing RING domain dimerization and E2 ubiquitin donor binding and activation. The CARD domain- mediated autoinhibition of the E3 ubiquitin-protein ligase activity suppresses cell proliferation and migration. USP19 regulates the stability of BIRC2/c-IAP1 by preventing its ubiquitination. Belongs to the IAP family. Note: This description may include information from UniProtKB.
Protein type: Ligase; Ubiquitin conjugating system; EC 6.3.2.-; Ubiquitin ligase
Chromosomal Location of Human Ortholog: 11q22
Cellular Component: cytosol; internal side of plasma membrane; lipid raft; nucleus; spindle microtubule; XY body
Molecular Function: caspase inhibitor activity; ligase activity; protein binding; protein N-terminus binding; transcription coactivator activity; ubiquitin-protein ligase activity; zinc ion binding
Biological Process: apoptosis; cell structure disassembly during apoptosis; cell surface receptor linked signal transduction; I-kappaB kinase/NF-kappaB cascade; innate immune response; MyD88-independent toll-like receptor signaling pathway; negative regulation of apoptosis; placenta development; positive regulation of I-kappaB kinase/NF-kappaB cascade; programmed cell death; proteasomal ubiquitin-dependent protein catabolic process; protein heterooligomerization; protein polyubiquitination; regulation of apoptosis; regulation of cell cycle; regulation of cell differentiation; regulation of cell proliferation; regulation of inflammatory response; regulation of innate immune response; regulation of toll-like receptor signaling pathway; regulation of transcription, DNA-dependent; response to cAMP; response to ethanol; response to hypoxia; toll-like receptor 3 signaling pathway; toll-like receptor 4 signaling pathway; toll-like receptor signaling pathway; transcription, DNA-dependent; tumor necrosis factor-mediated signaling pathway
Reference #:  Q13490 (UniProtKB)
Alt. Names/Synonyms: API1; apoptosis inhibitor 1; baculoviral IAP repeat-containing 2; Baculoviral IAP repeat-containing protein 2; BIRC2; C-IAP1; cIAP1; hIAP-2; hIAP2; IAP homolog B; IAP-2; IAP2; Inhibitor of apoptosis protein 2; MIHB; NFR2-TRAF signalling complex protein; RING finger protein 48; RNF48; TNFR2-TRAF-signaling complex protein 2
Gene Symbols: BIRC2
Molecular weight: 69,900 Da
Basal Isoelectric point: 6.27  Predict pI for various phosphorylation states
CST Pathways:  Apoptosis Regulation  |  Death Receptor Signaling  |  Inhibition of Apoptosis
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

BIRC2

Protein Structure Not Found.


STRING  |  cBioPortal  |  Wikipedia  |  Reactome  |  neXtProt  |  Protein Atlas  |  BioGPS  |  Scansite  |  Pfam  |  RCSB PDB  |  Phospho3D  |  Phospho.ELM  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene


Modification Sites and Domains  
Click here to view other types of protein modifications

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment


 LTP 

LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 HTP 

HTP: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 1 K19‑ub GPSYQNIkSIMEDST
0 1 K36‑ub SDWTNSNkQKMkYDF
0 1 K40‑ub NSNkQKMkYDFSCEL
0 1 K82 TGVNDKVKCFCCGLM
0 1 K94 GLMLDNWKLGDsPIQ
0 2 S98‑p DNWKLGDsPIQKHKQ
0 1 S123 LVSASLGSTSkNTSP
0 4 K126‑ub ASLGSTSkNTSPMRN
0 1 S129 GSTSkNTSPMRNSFA
0 4 S140‑p NSFAHSLsPTLEHSs
0 2 - gap
0 2 S147‑p sPTLEHSsLFSGSYS
0 2 S157‑p SGSYSSLsPNPLNSR
0 3 N159 SYSSLsPNPLNSRAV
0 4 Y177‑p SSSRTNPySYAMSTE
0 2 K226‑ub ACFACGGkLSNWEPk
0 5 K233‑ub kLSNWEPkDDAMSEH
0 1 S253‑p NCPFLENsLETLRFS
0 1 K305‑ub VGRNDDVkCFCCDGG
0 1 K340‑ub CEFLIRMkGQEFVDE
0 1 K410‑ub GFNRDLVkQTVQSkI
0 2 K416‑ub VkQTVQSkILTTGEN
0 2 K425‑ub LTTGENYkTVNDIVS
0 4 K441‑ub LLNAEDEkREEEkEk
0 5 K446‑ub DEkREEEkEkQAEEM
0 4 K448‑ub kREEEkEkQAEEMAS
0 1 K537‑ub EIDSTLYkNLFVDKN
0 1 K546‑ub LFVDKNMkYIPTEDV
0 1 S557‑p TEDVSGLsLEEQLRR
  mouse

 
K19 GTLHQKLKRIMEKST
E36 SNWTKESEEKMKFDF
K40 KESEEKMKFDFSCEL
K82‑ub TGVNDKVkCFCCGLM
K94‑ub GLMLDNWkQGDSPVE
S98 DNWkQGDSPVEKHRQ
S123‑p LLSASLQsPSKNMsP
K126 ASLQsPSKNMsPVKS
S129‑p QsPSKNMsPVKSRFA
S139 KSRFAHSSPLErGGI
R143‑m1 AHSSPLErGGIHSNL
- gap
C151 GGIHSNLCSsPLNSR
S153‑p IHSNLCSsPLNSRAV
C170 FSSRMDPCSYAMSTE
K219 ACFACGGKLSNWEPK
K226 KLSNWEPKDDAMSEH
T246 HCPFLENTSETQRFS
K298 VDRNDDVKCFCCDGG
K333 CEFLIRMKGQEFVDE
R404 GFSRSLVRQTVQRQI
Q410 VRQTVQRQILATGEN
R419 LATGENYRTVNDIVS
R435 LLNAEDERREEEKER
K440 DERREEEKERQTEEM
R442 RREEEKERQTEEMAS
E531 EIDSTLYENLFVEKN
K540 LFVEKNMKYIPTEDV
S551 TEDVSGLSLEEQLRR
  rat

 
- gap
K15 SNWTKENKEKMKYDF
K19 KENKEKMKYDFSCEL
K61 TGVNDKVKCFCCGLM
K73 GLMLDNWKQGDSPTE
S77 DNWKQGDSPTEKHRQ
S102 LLSGGLQSAAKNTSP
K105 GGLQSAAKNTSPAKS
S108 QSAAKNTSPAKSRFA
L118 KSRFAHSLPLEQGGI
Q122 AHSLPLEQGGIHSSL
- gap
P130 GGIHSSLPSNPLNSR
N132 IHSSLPSNPLNSRAV
C149 FSLRMNPCSYAMSTE
K198 ACFACGGKLSNWEPN
N205 KLSNWEPNDDPLSEH
T225 HCPFLENTSETQRFS
K277 VDHNDDVKCFCCDGG
K312 CEFLIRMKGQEFVDE
R381 GFSRSLVRQTVQRQI
Q387 VRQTVQRQILATGEN
R396 LATGENYRTVSDIVS
R412 LLNAEDERREEEKER
K417 DERREEEKERQSEET
R419 RREEEKERQSEETAS
E508 EVDSTLYEHLFVEKT
K517 LFVEKTMKYIPTEDV
S528 TEDVSGLSLEEQLRR
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.